Innate Pharma SA (IPHA) stock

IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30

$1.49−0.10 (-6.29%)

Close on Nov 12, 2026Market cap $139.64MP/E –Yield –

Innate Pharma r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was €43.62M, down 16.1% from the year before. The highest annual figure on record is €69.56M in fiscal 2018.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	€43.62M	-16.1%
FY2024	Dec 31, 2024	€51.98M	-7.2%
FY2023	Dec 31, 2023	€56.02M	+8.4%
FY2022	Dec 31, 2022	€51.66M	+9.9%
FY2021	Dec 31, 2021	€47.00M	-5.4%
FY2020	Dec 31, 2020	€49.71M	-21.0%
FY2019	Dec 31, 2019	€62.90M	-9.6%
FY2018	Dec 31, 2018	€69.56M	+3.8%
FY2017	Dec 31, 2017	€67.00M	–

Parsed from the XBRL in Innate Pharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IPHA.

Revenue growth-55.2% · median -38.4%

Operating margin-599.8% · median -1140.6%

Advertisement
300 × 250

See a number that looks wrong?